NEUROLOGY 1997;49:S66-S69
© 1997 American Academy of Neurology
Cerestat and other NMDA antagonists in ischemic stroke
Kennedy R. Lees, BSc, MD, FRCP
From the Acute Stroke Unit, University Department of Medicine & Therapeutics, Western Infirmary, Glasgow, Scotland.
Address correspondence and reprint requests to Dr. Kennedy R. Lees, Clinical Director, Acute Stroke Unit, University Department of Medicine & Therapeutics, Western Infirmary, Glasgow G11 6NT, Scotland.
Abstract.
A wealth of experimental evidence demonstrates that cerebral ischemia cause excessive release of glutamate and that glutamate contributes to ischemic injury. Glutamate antagonism by any of several mechanisms can ameliorate the extent of infarction. These antagonists comprise noncompetitive blockers of the ion channel associated with the N-methyl-D-aspartate (NMDA) receptor [e.g., aptiganel (Cerestat)], competitive antagonists of the glutamate recognition site of the NMDA receptor (e.g., selfotel) or of the glycine recognition site (e.g., ACEA 1021, GV150526), antagonists at the polyamine site (e.g., eliprodil), and drugs that may interfere with glutamate release by sodium channel blockade as well as having other actions (e.g., lubeluzole, 619C89). Clinical experience suggests that although some NMDA antagonists are poorly tolerated at putative neuroprotective doses (e.g., selfotel), potentially neuroprotective plasma concentrations can be achieved in humans with others (e.g., aptiganel), though tolerable adverse effects are frequently observed. These clinical effects include hypertension (which is probably preferable to the hypotension seen with nimodipine and lifarizine), sedation, confusion or hallucinations and, at high doses, catatonia. Glycine antagonists may be associated with fewer adverse effects, but preclinical studies suggest that brain penetration may be low. Although recent studies with selfotel and eliprodil have been discontinued because of insufficient evidence for a satisfactory risk/benefit ratio, encouraging experience with aptiganel, magnesium, and glycine antagonists has prompted continued clinical trials with these agents. To be of sufficient size to detect a clinically useful improvement in outcome, these trials need to be large (600-1,000 patients). Present trials with aptiganel (Cerestat) are comparing the efficacy and tolerability of two doses vs. placebo in patients treated within 6 hours of ischemic stroke. Outcome is assessed by the modified Rankin Scale at 3 months.
This article has been cited by other articles:
|
|
|
|
 
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Circulation,
May 22, 2007;
115(20):
e478 - e534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Stroke,
May 1, 2007;
38(5):
1655 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Danton and W. D. Dietrich
The Search for Neuroprotective Strategies in Stroke
AJNR Am. J. Neuroradiol.,
February 1, 2004;
25(2):
181 - 194.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Junge, T. Sugawara, G. Mannaioni, S. Alagarsamy, P. J. Conn, D. J. Brat, P. H. Chan, and S. F. Traynelis
The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia
PNAS,
October 28, 2003;
100(22):
13019 - 13024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Crocco, T. Gullett, S. M. Davis, N. Flores, L. Sauerbeck, E. Jauch, B. Threlkeld, B. Pio, M. Ottaway, A. Pancioli, et al.
Feasibility of Neuroprotective Agent Administration by Prehospital Personnel in an Urban Setting
Stroke,
August 1, 2003;
34(8):
1918 - 1922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Ryu, Y. A. Lee, S. J. Won, J.-H. Noh, S.-Y. Chang, J.-M. Chung, J. S. Choi, C. K. Joo, S. H. Yoon, and B. J. Gwag
The Novel Neuroprotective Action of Sulfasalazine through Blockade of NMDA Receptors
J. Pharmacol. Exp. Ther.,
April 1, 2003;
305(1):
48 - 56.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J.-W. Elting, G. A. Sulter, M. Kaste, K. R. Lees, H. C. Diener, M. Hommel, M. Versavel, A. W. Teelken, and J. De Keyser
AMPA Antagonist ZK200775 in Patients With Acute Ischemic Stroke: Possible Glial Cell Toxicity Detected by Monitoring of S-100B Serum Levels
Stroke,
December 1, 2002;
33(12):
2813 - 2818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gill, A. Alanine, A. Bourson, B. Buttelmann, G. Fischer, M.-P. Heitz, J. N. C. Kew, B. Levet-Trafit, H.-P. Lorez, P. Malherbe, et al.
Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a Novel Subtype-Selective N-Methyl-D-Aspartate Antagonist
J. Pharmacol. Exp. Ther.,
September 1, 2002;
302(3):
940 - 948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G DEVUYST and J BOGOUSSLAVSKY
Recent progress in drug treatment for acute stroke
J. Neurol. Neurosurg. Psychiatry,
October 1, 1999;
67(4):
420 - 425.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dingledine, K. Borges, D. Bowie, and S. F. Traynelis
The Glutamate Receptor Ion Channels
Pharmacol. Rev.,
March 1, 1999;
51(1):
7 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
